Novartis restructures of global collaboration with Schering-Plough for fixed-dose combination respiratory therapies
Novartis assumes exclusive worldwide development and marketing rights for investigational once-daily QMF149 being developed for COPD and asthma
Novartis has assumed exclusive worldwide rights to develop and commercialize QMF149, a fixed-combination of its investigational QAB149 (indacaterol) with Schering-Plough Corporation's inhaled corticosteroid mometasone, in changes announced to the companies' collaboration to develop fixed-dose combination respiratory therapies.
In development for chronic obstructive pulmonary disease (COPD) and asthma, QMF149 combines the anti-inflammatory properties of mometasone with the bronchodilation of QAB149, a long-acting beta2-adrenergic agonist.
Under the new agreement with Schering-Plough, Novartis assumes exclusive worldwide rights to develop and commercialize QMF149. Schering-Plough assumes exclusive rights to develop and commercialize a fixed-combination of mometasone plus the Novartis product Foradil® (formoterol), another long-acting beta2-adrenergic agonist.
Novartis will assume the remaining development and commercialization costs for the QAB149 (indacaterol)/mometasone combination, including use of the Twisthaler® device, while the remaining development and future commercialization costs of the formoterol/mometasone combination, including use of a pMDI device, will be borne by Schering-Plough. There will be a royalty sharing arrangement based on sales. Novartis will also recognize sales worldwide for QMF149 upon commercialization.
QAB149 (indacaterol) is currently under regulatory review. In December 2008, Novartis submitted regulatory dossiers for approval of indacaterol in the United States and the European Union. Mometasone and formoterol are currently marketed under the trade names Asmanex® and Foradil®, respectively.
This transaction is subject to customary regulatory approvals.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Arakis commences Phase IIB trial for rheumatoid arthritis drug

Why Doesn’t Honey Spoil?
Abgenix Appoints Donald R. Joseph as Senior Vice President, General Counsel and Secretary
Ablynx announces cancer immunotherapy discovery collaboration with Merck
Category:Vascular_surgery
Study finds breast and ovarian cancer may have similar origins
Evonik ends cooperation with Chr. Hansen
Category:Female_sexual_dysfunction_drugs

Frederick W. Alt and David G. Schatz to be awarded the 2023 Paul Ehrlich and Ludwig Darmstaedter Prize - Laureates raised knowledge of the development of the immune system to a new level
Chemotherapy timing is key to success - Nanoparticles that stagger delivery of 2 drugs knock out aggressive tumors in mice

Call for Entries: Eppendorf & Science Prize for Neurobiology 2017
